The background, discovery and clinical development of BCR-ABL inhibitors

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Chronic myelogenous leukemia (CML) treatment historically involved limited options.
• The discovery of the BCR-ABL fusion protein as a key driver of CML was a significant breakthrough.

Purpose of the Study:

• To illustrate the kinase drug discovery and development process using the example of BCR-ABL inhibition.
• To highlight the challenges of drug resistance and the strategies to overcome them.

Main Methods:

• Elucidation of the CML disease mechanism to identify the BCR-ABL molecular target.
• Pharmaceutical research and rational drug design to develop targeted inhibitors.
• Development of second-generation inhibitors to address resistance.

Main Results:

• Identification of BCR-ABL as a therapeutic target.
• Development of the first FDA-approved BCR-ABL inhibitor, Gleevec®.
• Emergence of drug resistance mechanisms.
• Successful development of second-generation BCR-ABL inhibitors.

Conclusions:

• Targeted kinase inhibition is a successful strategy for cancer treatment.
• Rational drug design is crucial for overcoming acquired drug resistance.
• Advancements in kinase inhibitor development provide expanded therapeutic choices for patients.